New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238)); influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like strain (a/california/122/2022, san-022)); influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type)); influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type)) - suspension for injection - 60 mcg - active: influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238)) influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like strain (a/california/122/2022, san-022)) influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type)) influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type)) excipient: octoxinol 9 phosphate buffered saline - fluquadri is indicated for active immunisation of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. fluquadri is indicated for use in adults and children 6 months and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a (h1n1) haemagglutinin 7.5ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))); influenza virus a (h3n2) haemagglutinin 7.5ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))); influenza virus b (victoria) haemagglutinin 7.5ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))); influenza virus b (yamagata) haemagglutinin 7.5ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) - suspension for injection - 30 mcg/0.25ml - active: influenza virus a (h1n1) haemagglutinin 7.5ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))) influenza virus a (h3n2) haemagglutinin 7.5ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))) influenza virus b (victoria) haemagglutinin 7.5ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))) influenza virus b (yamagata) haemagglutinin 7.5ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) excipient: calcium chloride dihydrate dibasic sodium phosphate monobasic potassium phosphate monobasic sodium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. afluria quad junior vaccine is indicated for use in children aged 6 months to 35 months inclusive. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Ireland - English - HPRA (Health Products Regulatory Authority)

wellcome (ireland) limited -

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - a/singapore /6/86 (h1n1)-like strain a/wuhan /359/95 (h3n2)-like strain b/beijing /184/93-like strain - solution for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a/johannesburg/33/94 15ug (1996 season); influenza virus a/texas/36/91 h1n1 15ug (1996 season); influenza virus b/harbin/7/94 15ug - solution for injection - 15µg ha/0.5ml - active: influenza virus a/johannesburg/33/94 15ug (1996 season) influenza virus a/texas/36/91 h1n1 15ug (1996 season) influenza virus b/harbin/7/94 15ug excipient: gelatin thiomersal

Canada - English - Health Canada

aventis pasteur inc. - influenza virus vaccine - liquid - 45mcg - influenza virus vaccine 45mcg - vaccines

Canada - English - Health Canada

sanofi pasteur limited - a/panama/2007/99 (h3n2) -like strain; a/new caledonia/20/99(h1n1)-like strain; b/hong kong/1434/2002-like strain - suspension - 15mcg; 15mcg; 15mcg - a/panama/2007/99 (h3n2) -like strain 15mcg; a/new caledonia/20/99(h1n1)-like strain 15mcg; b/hong kong/1434/2002-like strain 15mcg - vaccines

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 60ug (a/michigan/45/2015, x-275); influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 60ug (a/singapore/infimh-16-0019/2016, nib-104); influenza virus b/phuket/3073/2013 - like strain 60ug (b/phuket/3073/2013 (yamagata lineage)) - suspension for injection - 180 mcg/dose - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 60ug (a/michigan/45/2015, x-275) influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 60ug (a/singapore/infimh-16-0019/2016, nib-104) influenza virus b/phuket/3073/2013 - like strain 60ug (b/phuket/3073/2013 (yamagata lineage)) excipient: dibasic sodium phosphate monobasic sodium phosphate octoxinol 9 sodium chloride water for injection - for active immunisation against influenza disease caused by influenza virus subtypes a and type b contained in the vaccine for use in persons 65 years of age and older.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmatrade united states of america - 10 single-dose pre-filled syringes (0.7 ml) - injection - 60 µg/60 µg/60 µg/60 µg/pre-filled syringe - immunologicals , vaccines-vaccines , antisera

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmatrade united states of america - 10 single-dose pre-filled syringes (0.7 ml) - injection - 60 µg/60 µg/60 µg/60 µg/pre-filled syringe - immunologicals , vaccines-vaccines , antisera